Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma

Brinkman, Paul; Wagener, Ariane H.; Hekking, Pieter Paul; Bansal, Aruna T.; Zee, Anke‐Hilse Maitland‐van der; Wang, Yuanyue; Weda, Hans; Knobel, Hugo H.; Vink, T. J.; Rattray, Nicholas J. W.; D’Amico, A.; Pennazza, Giorgio; Santonico, Marco; Lefaudeux, Diane; Meulder, Bertrand De; Auffray, Charles; Bakke, Per; Caruso, Massimo; Chanez, Pascal; Chung, Kian Fan; Corfield, Julie; Dahlén, Sven Erik; Djukanović, Ratko; Geiser, Thomas; Horváth, Ildikó; Krug, N; Musiał, Jacek; Sun, Kai; Riley, John; Shaw, Dominick; Sandström, Thomas; Sousa, Ana R.; Montuschi, Paolo; Fowler, Stephen J.; Sterk, Peter J.

doi:10.1016/j.jaci.2018.10.058

Cited by 80 publications

(71 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Assays involving exhaled breath appear promising in terms of finding out useful predictive bedside biomarkers. Real‐time analysis of metabolites in exhaled breath using a set of “electronic noses” could discriminate with a high degree of accuracy between the 3 TACs determined by hierarchical clustering of differentially expressed genes in sputum . However, the basis for this good predictability remains unclear.…”

Section: Treatable Mechanisms and Targeted Treatmentsmentioning

confidence: 99%

Precision medicine for the discovery of treatable mechanisms in severe asthma

Chung

Adcock

2019

Allergy

View full text Add to dashboard Cite

Although the complex disease of asthma has been defined as being heterogeneous, the extent of its endophenotypes remains unclear. The pharmacological approach to initiating treatment has, until recently, been based on disease control and severity.The introduction of antibody therapies targeting the Type 2 inflammation pathway for patients with severe asthma has resulted in the recognition of an allergic and an eosinophilic phenotype, which are not mutually exclusive. Concomitantly, molecular phenotyping based on a transcriptomic analysis of bronchial epithelial and sputum cells has identified a Type 2 high inflammation cluster characterized by eosinophilia and recurrent exacerbations, as well as Type 2 low clusters linked with IL-6 trans-signalling, interferon pathways, inflammasome activation and mitochondrial oxidative phosphorylation pathways. Systems biology approaches are establishing the links between these pathways or mechanisms, and clinical and physiologic features.Validation of these pathways contributes to defining endotypes and treatable mechanisms. Precision medicine approaches are necessary to link treatable mechanisms with treatable traits and biomarkers derived from clinical, physiologic and inflammatory features of clinical phenotypes. The deep molecular phenotyping of airway samples along with noninvasive biomarkers linked to bioinformatic and machine learning techniques will enable the rapid detection of molecular mechanisms that transgresses beyond the concept of treatable traits. K E Y W O R D Seosinophilic asthma, precision medicine, severe asthma, systems biology

show abstract

Section: Treatable Mechanisms and Targeted Treatmentsmentioning

confidence: 99%

Precision medicine for the discovery of treatable mechanisms in severe asthma

Chung

Adcock

2019

Allergy

View full text Add to dashboard Cite

show abstract

“…Wheelock et al nicely reviewed sophisticated large-scale analytical methods to quantify gene expression (transcriptomics), proteins (proteomics), lipids (lipidomics), and metabolites (metabolomics) in various samples, including blood, and as far as pulmonary diseases are concerned, induced sputum, bronchial biopsies, epithelial brushings, and bronchoalveolar lavages (67). Moreover, measurements of volatile organic compounds (VOCs) found in exhaled air and exhaled air condensates (volatolomics, exhalomics) can be addressed as well as the integration of inhaled pollutants and other allergens (exposomics), and more recently characterized pulmonary microbiota (68)(69)(70) (Figure 1).…”

Section: Toward a Systems Approach In Asthma: Unbiased Omics Studies mentioning

confidence: 99%

Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments

2020

View full text Add to dashboard Cite

Asthma is a frequent heterogeneous multifactorial chronic disease whose severe forms remain largely uncontrolled despite the availability of many drugs and educational therapy. Several phenotypes and endotypes of severe asthma have been described over the last two decades. Typical type-2-immunity-driven asthma remains the most frequent phenotype, and several targeted therapies have been developed and are now available. On the contrary, non-type-2 immunity-driven severe asthma is less understood and still requires efficient innovative therapies. A personalized approach would allow improving asthma control with the help of robust biomarkers able to predict phenotypes/endotypes, exacerbations, response to targeted treatments and, in the future, possible curative options. Some data from large multicenter cohorts have emerged in recent years, especially in transcriptomics. These data have to be integrated and reproduced longitudinally to provide a systems approach for asthma care. In this focused review, the needs for such an approach and the available data will be reviewed as well as the next steps for achieving personalized medicine in asthma.

show abstract

“…Easy-to-use devices measuring exhaled air parameters were highlighted on several occasions as valuable support for the rapid, noninvasive and early detection of asthma, especially in symptomatic children [21]. Molecular biomarkers such as exhaled volatile organic compounds (VOCs) can be detected by electronic nose technology for metabolomic analyses [22] and VOCs measured by gas chromatography-time-of-flight mass spectrometry have been able to discriminate between various asthma inflammatory phenotypes [23]. The Inflammacheck (Exhalation Technology, Cambridge, UK) device could detect exhaled hydrogen peroxide as a marker of lung disease, including mild and severe asthma [24].…”

Section: Biomarkersmentioning

confidence: 99%

ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly

et al. 2020

View full text Add to dashboard Cite

The European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, was a platform for scientific discussion of the highest quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses some of the high-quality research studies presented at that Congress, with a focus on airway diseases, including asthma, COPD, small airways, bronchiectasis and cough, presented through the Airway Diseases, Asthma and COPD Assembly (Assembly 5) of the ERS. The authors establish the key take-home messages of these studies, compare their findings and place them into context of current understanding.

show abstract

Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma

Abstract: Identification and prospective stability of eNose derived inflammatory phenotypes in severe asthma.

Cited by 80 publications

References 62 publications

Precision medicine for the discovery of treatable mechanisms in severe asthma

Precision medicine for the discovery of treatable mechanisms in severe asthma

Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments

ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly

Contact Info

Product

Resources

About